In recent years, open access has provided new audiences, including patients, the general public and doctors in low and middle income countries (LMICs), with direct, free access to the results of scientific research.
MPIP launches new open access toolkit
A new reference site from Medical Publishing Insights and Practices (MPIP) aims to educate its users on the ins and outs of open access as part of its commitment to improving research transparency in pharma. With open access everywhere nowadays, it is very important to know what it is and how it works. However, this … Continue reading MPIP launches new open access toolkit
Predatory publishing on the Open Pharma podcast
Open access is a fantastic opportunity to make science accessible to all. Find out how to get all of the benefits without fearing the predators in our new podcast!
Increasing transparency in biomedical research: CBMRT
In order to protect the quality of clinical research it is vital for all trials to be represented in scientific literature for the benefit of scientific progress and research efficiency, and, ultimately, to better inform care for our patients in a timely manner.
How Crossref can help medical publishing professionals
CrossRef is a nonprofit whose goal is to catalogue metadata about scholarly works in order to facilitate easier access and correct record keeping--and they might just become medical publishers’ new best friend.
Patients in publications – where are we now?
Patient engagement in medical research is a priority for the pharmaceutical industry; however, patient involvement in publications is rare.
Perspectives on open access from the 14th Annual Meeting of ISMPP
Open access publishing of medical research is increasingly prevalent, but open access terminology is varied and confusing. Gold, green, bronze, hybrid, CC BY, CC BY-NC – what does it all mean, and what is the best type of open access? At the 14th Annual Meeting of the International Society of Medical Publication Professionals, a panel of stakeholders in medical publications met to discuss open access from different perspectives.
What do preprints mean for medical publishing?
Preprints are all around us – but are they relevant and useful or too risky for industry-sponsored research? Two sessions at the 14th Annual Meeting of ISMPP held in Washington this month kicked off the first major public discussions on preprints in our medical communications community.
Time to embrace change in medical publishing?
At this year’s ISMPP European meeting, a panel of Open Pharma members discussed open access, preprints and post-publication peer review, and the possibility of utilizing these tools to make the publishing of pharmaceutical research faster and more transparent.
Tools supporting ethics and integrity in submission and review
With CRediT, ORCID and Publons integrated into Editorial Manager®, we aim for these transparency tools to be easy, standard steps in the publishing process